Mihai Gheorghiade

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Congestion is an important diagnostic and therapeutic target in heart failure
    Mihai Gheorghiade
    Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Rev Cardiovasc Med 7:S12-24. 2006
  2. doi request reprint Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure
    Mihai Gheorghiade
    Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Am Coll Cardiol 51:2276-85. 2008
  3. ncbi request reprint Therapy for acute heart failure syndromes
    Sarah M Donlan
    Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, 259 East Erie Street, Suite 100, Chicago, IL 60611, USA
    Curr Cardiol Rep 11:192-201. 2009
  4. ncbi request reprint Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue, Suite 1006, Chicago, 60611, IL, USA
    Heart Fail Rev 19:135-52. 2014
  5. ncbi request reprint Anticoagulation in heart failure: current status and future direction
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue, Suite 1006, Chicago, IL, 60611, USA
    Heart Fail Rev 18:797-813. 2013
  6. doi request reprint Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL 60611, USA
    Eur J Heart Fail 15:679-89. 2013
  7. doi request reprint Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Chicago, IL 60611, USA
    Heart Fail Clin 9:285-90, v-vi. 2013
  8. doi request reprint Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    JAMA 309:1125-35. 2013
  9. doi request reprint Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure
    Mihai Gheorghiade
    Center of Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL 60611, USA
    Heart Fail Rev 18:107-22. 2013
  10. doi request reprint Soluble guanylate cyclase: a potential therapeutic target for heart failure
    Mihai Gheorghiade
    Center of Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL 60611, USA
    Heart Fail Rev 18:123-34. 2013

Collaborators

Detail Information

Publications136 found, 100 shown here

  1. ncbi request reprint Congestion is an important diagnostic and therapeutic target in heart failure
    Mihai Gheorghiade
    Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Rev Cardiovasc Med 7:S12-24. 2006
    ..Identification of hemodynamic congestion, before the clinical manifestations appear, may potentially prevent hospitalization and slow the progression of HF by allowing life-saving interventions to be implemented sooner...
  2. doi request reprint Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure
    Mihai Gheorghiade
    Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Am Coll Cardiol 51:2276-85. 2008
    ..We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in patients hospitalized with heart failure (HF)...
  3. ncbi request reprint Therapy for acute heart failure syndromes
    Sarah M Donlan
    Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, 259 East Erie Street, Suite 100, Chicago, IL 60611, USA
    Curr Cardiol Rep 11:192-201. 2009
    ..We review the use of these therapies in AHFS with added insights from recent clinical trials and registry data...
  4. ncbi request reprint Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue, Suite 1006, Chicago, 60611, IL, USA
    Heart Fail Rev 19:135-52. 2014
    ....
  5. ncbi request reprint Anticoagulation in heart failure: current status and future direction
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue, Suite 1006, Chicago, IL, 60611, USA
    Heart Fail Rev 18:797-813. 2013
    ..These data suggest there is a need to assess the potential role for these newer agents in the management of patients hospitalized for HF who continue to have a high post-discharge event rate despite available therapies. ..
  6. doi request reprint Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL 60611, USA
    Eur J Heart Fail 15:679-89. 2013
    ..We examined the safety, pharmacokinetics, and effects on haemodynamics and serum biomarkers of intravenous human stresscopin acetate (JNJ-39588146) in patients with stable HF with LVEF ≤ 35% and cardiac index (CI) ≤ 2.5 L/min/m(2)...
  7. doi request reprint Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Chicago, IL 60611, USA
    Heart Fail Clin 9:285-90, v-vi. 2013
    ..This article summarizes concepts in developing therapies for HHF discussed during a multidisciplinary panel at the Heart Failure Society of America's Annual Scientific Meeting, September 2012. ..
  8. doi request reprint Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    JAMA 309:1125-35. 2013
    ..Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality...
  9. doi request reprint Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure
    Mihai Gheorghiade
    Center of Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL 60611, USA
    Heart Fail Rev 18:107-22. 2013
    ....
  10. doi request reprint Soluble guanylate cyclase: a potential therapeutic target for heart failure
    Mihai Gheorghiade
    Center of Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL 60611, USA
    Heart Fail Rev 18:123-34. 2013
    ....
  11. doi request reprint Rehospitalization for heart failure: problems and perspectives
    Mihai Gheorghiade
    Center for Cardiovascular Innovation at Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Am Coll Cardiol 61:391-403. 2013
    ....
  12. ncbi request reprint Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes
    Mihai Gheorghiade
    Centre for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave, Suite 1006, Chicago, IL 60611, USA
    Eur J Heart Fail 14:1056-66. 2012
    ..The aim of the COMPOSE programme was to investigate the safety and efficacy of fixed, low doses of intravenous cinaciguat (<200 µg/h for 24-48 h) as add-on to standard therapy in adults hospitalized with AHFS...
  13. doi request reprint A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Heart Fail Rev 17:485-509. 2012
    ..Identifying these abnormalities may facilitate efforts to reduce post-discharge mortality and re-hospitalization...
  14. doi request reprint Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Congest Heart Fail 18:9-17. 2012
    ..Additional research to determine barriers to use of target doses of HF medications may be necessary...
  15. ncbi request reprint Neurohormonal inhibition in heart failure: insights from recent clinical trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, 201 East Huron Street, Chicago, IL 60611, USA
    Am J Cardiol 96:3L-9L. 2005
    ....
  16. ncbi request reprint Contemporary use of digoxin in the management of cardiovascular disorders
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Circulation 113:2556-64. 2006
  17. doi request reprint Nutritional supplementation with amino acids in cardiovascular and metabolic diseases: hypermetabolic syndrome as a therapeutic target. Introduction
    Mihai Gheorghiade
    Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 101:1E-2E. 2008
  18. ncbi request reprint Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, 201 E Huron Street, Chicago, IL 60611, USA
    Arch Intern Med 167:1998-2005. 2007
    ..To our knowledge, the association of hyponatremia with outcomes has not been evaluated in the context of in-hospital clinical course including central hemodynamics and changes in serum sodium level...
  19. ncbi request reprint Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 297:1332-43. 2007
    ..Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition...
  20. ncbi request reprint The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 96:18G-25G. 2005
    ..Accordingly, therapies for AHFS that are aimed at improving hemodynamics may affect long-term prognosis by either injuring or salvaging myocardium...
  21. ncbi request reprint The clinical effects of vasopressin receptor antagonists in heart failure
    Mihai Gheorghiade
    Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Cleve Clin J Med 73:S24-9; discussion S30-3. 2006
    ..In placebo-controlled trials in the inpatient and outpatient setting, the AVP receptor antagonist tolvaptan reduced body weight and edema and normalized serum sodium in patients with heart failure...
  22. ncbi request reprint Pharmacology of new agents for acute heart failure syndromes
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 96:68G-73G. 2005
    ..Therefore, by using novel mechanisms of action, these agents may provide new opportunities for helping patients with AHFS...
  23. ncbi request reprint The challenge of acute heart failure syndromes
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 96:86G-9G. 2005
  24. ncbi request reprint Congestion in acute heart failure syndromes: an essential target of evaluation and treatment
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Am J Med 119:S3-S10. 2006
    ..Accordingly, the assessment and management of pulmonary and systemic congestion in these patients require reevaluation...
  25. ncbi request reprint Introduction to acute heart failure syndromes
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 96:1G-4G. 2005
  26. ncbi request reprint Pathophysiologic targets in the early phase of acute heart failure syndromes
    Mihai Gheorghiade
    Division of Cardiology, Northwester University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 96:11G-17G. 2005
    ..The goals of therapy for AHFS should be not only to improve symptoms and hemodynamics, but also to preserve or improve renal function and prevent myocardial damage...
  27. ncbi request reprint Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry
    Mihai Gheorghiade
    Division of Cardiology, Feinberg School of Medicine, Northwestern University, Galter 10 240, 201 E Huron Street, Chicago, IL 60611, USA
    Eur Heart J 28:980-8. 2007
    ..The predictive value of hyponatraemia has not been evaluated in unselected patients hospitalized with heart failure...
  28. ncbi request reprint Management of post-myocardial infarction patients with left ventricular systolic dysfunction
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am J Med 120:109-20. 2007
    ..These trials have defined the benefits of pharmacologic management and device therapy in patients who survive an MI in the presence of LVSD...
  29. ncbi request reprint Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 97:1064-7. 2006
    ..No differences in adverse events were observed between the groups. In conclusion, tolvaptan appears to be more effective than fluid restriction at correcting hyponatremia in hospitalized subjects, without an increase in adverse events...
  30. ncbi request reprint Acute heart failure syndromes: current state and framework for future research
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circulation 112:3958-68. 2005
  31. doi request reprint Digoxin for the treatment of chronic and acute heart failure syndromes
    Mihai Gheorghiade
    Department of Medicine, Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Acute Card Care 11:83-7. 2009
    ..This report represents a summary of the presentation at this meeting...
  32. doi request reprint The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction
    Mihai Gheorghiade
    Department of Medicine, Center for Cardiovascular Quality and Outcomes, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Am Heart J 158:437-43. 2009
    ....
  33. doi request reprint Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase
    Mihai Gheorghiade
    Experimental Therapeutics, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Am Heart J 161:224-32. 2011
    ..In this brief report, we outline the T1 or translational phase of research for AHFS clinical development as an important first step toward greater success in AHFS clinical trials...
  34. doi request reprint Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion
    Luna Gargani
    Institute of Clinical Physiology, National Council of Research of Pisa, Pisa, Italy
    Expert Rev Cardiovasc Ther 9:1505-13. 2011
    ..However, further clinical trials are needed to determine the optimal dosing, proper monitoring and adequate precautions for the use of vaptans in this patient population...
  35. ncbi request reprint Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial
    Mihai Gheorghiade
    Northwestern University Feinberg School of Medicine, 201 East Huron St, Galter 10 240, Chicago, Ill 60611, USA
    Circulation 107:2690-6. 2003
    ..In this study, we evaluated the effects of tolvaptan (OPC-41061), a novel, oral, nonpeptide vasopressin V2-receptor antagonist in patients with chronic heart failure (CHF)...
  36. ncbi request reprint Beta-blockers in chronic heart failure
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611 2908, USA
    Circulation 107:1570-5. 2003
  37. ncbi request reprint Surrogate end points in heart failure trials
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S67-70. 2003
  38. ncbi request reprint Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S55-7. 2003
  39. ncbi request reprint Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S51-4. 2003
  40. ncbi request reprint Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial
    Michael S Cuffe
    Northwestern University Medical School, Division of Cardiology, 201 E Huron St, Galter 10 240, Chicago, IL 60611, USA
    JAMA 287:1541-7. 2002
    ..Although intravenous inotropic therapy usually produces beneficial hemodynamic effects and is labeled for use in the care of such patients, the effect of such therapy on intermediate-term clinical outcomes is uncertain...
  41. ncbi request reprint Beta-blockers in the post-myocardial infarction patient
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg Medical School, Chicago, Ill 60611, USA
    Circulation 106:394-8. 2002
  42. ncbi request reprint Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL 60601, USA
    Discov Med 12:141-51. 2011
    ....
  43. ncbi request reprint Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Ital Heart J 5:160-2. 2004
    ..We speculate that high-dose statin therapy had a significant role in improving the ventricular function in our patient by improving the endothelial flow. This hypothesis is presently being tested in a larger prospective trial...
  44. ncbi request reprint Digoxin in the management of cardiovascular disorders
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Galter 10 240, 201 East Huron St, Chicago, Ill 60611 2908, USA
    Circulation 109:2959-64. 2004
  45. doi request reprint The current and future management of acute heart failure syndromes
    Peter S Pang
    Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Eur Heart J 31:784-93. 2010
    ....
  46. doi request reprint Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Heart Lung Transplant 30:218-26. 2011
    ..The oral, direct Factor Xa inhibitor, rivaroxaban, has not been studied in patients with HF. We hypothesized that rivaroxaban would also reduce biomarkers of hypercoagulability in patients with HF...
  47. ncbi request reprint Role of carvedilol in atrial fibrillation: insights from clinical trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 93:53B-7B. 2004
    ..Additional recent studies suggest that carvedilol may be useful in managing postsurgical atrial fibrillation and also may prevent recurrence of atrial fibrillation among patients who undergo cardioversion...
  48. doi request reprint Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue, Suite 1006, Chicago, IL 60611, USA
    Eur J Heart Fail 13:100-6. 2011
    ..The aim of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) study is to evaluate the effect of aliskiren on cardiovascular death and HF in AHFS patients...
  49. ncbi request reprint Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 291:1963-71. 2004
    ..In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function...
  50. doi request reprint Heart failure in 2010: one step forward, two steps back
    Mihai Gheorghiade
    Center for Cardiovascular Innovation, Feinberg School of Medicine, Northwestern University, 645 North Michigan Avenue, Chicago, IL 60611, USA
    Nat Rev Cardiol 8:72-3. 2011
    ..HF trials in 2010 contributed to the advancement of outpatient management, whereas the development of novel therapies with a survival benefit remains an unmet need in acute HF syndromes...
  51. ncbi request reprint Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry
    Gregg C Fonarow
    Department of Medicine, Ahmanson UCLA Cardiomyopathy Center, Los Angeles, CA 90095 1679, USA
    Am Heart J 154:12-38. 2007
    ..Deidentified clinical data from the medical records of a planned 43,000 patients from 160 US cardiology practices will be included in this study...
  52. doi request reprint Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure)
    Gregg C Fonarow
    Department of Medicine, UCLA Medical Center, Los Angeles, CA, USA
    Am J Cardiol 102:1524-9. 2008
    ..In the first 60 to 90 days after hospital discharge, little up-titration in beta-blocker dosing occurs. Further efforts are needed to help understand and overcome this beta-blocker titration gap...
  53. ncbi request reprint Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
    J Card Fail 11:260-9. 2005
    ....
  54. ncbi request reprint Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    JAMA 297:1319-31. 2007
    ..Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure...
  55. ncbi request reprint Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure
    Mihai Gheorghiade
    Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill, USA
    JAMA 296:2217-26. 2006
    ..The association between systolic blood pressure (SBP) at admission, clinical characteristics, and outcomes in patients hospitalized for heart failure who have reduced or relatively preserved systolic function has not been well studied...
  56. doi request reprint Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF
    J Thomas Heywood
    Division of Cardiology, Scripps Clinic Torrey Pines, La Jolla, Calif 92037, USA
    Circ Heart Fail 3:596-605. 2010
    ..Few data exist to characterize the delivery of evidence-based medical therapy for outpatients with heart failure who have received implantable cardioverter-defibrillators or cardiac resynchronization therapy (CRT) for systolic dysfunction...
  57. ncbi request reprint Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry
    Gregg C Fonarow
    Ahmanson UCLA Cardiomyopathy Center, Department of Medicine, UCLA Medical Center, Los Angeles, California 90095 1679, USA
    J Am Coll Cardiol 50:768-77. 2007
    ..We sought to evaluate the characteristics, treatments, and outcomes of patients with preserved and reduced systolic function heart failure (HF)...
  58. doi request reprint Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial
    Satyam Sarma
    Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Eur J Heart Fail 15:194-202. 2013
    ..DM is prevalent in patients hospitalized with HF, yet inconclusive data exist on the post-discharge outcomes of this patient population...
  59. doi request reprint Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment
    James D Flaherty
    Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    J Am Coll Cardiol 53:254-63. 2009
    ..Prospective studies of the assessment and treatment of CAD in patients with AHFS are urgently needed...
  60. ncbi request reprint Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s
    Liviu Klein
    Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    Circulation 111:2454-60. 2005
    ..The prognostic value of serum sodium in patients hospitalized for worsening heart failure has not been well defined...
  61. doi request reprint Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in P
    Sanjiv J Shah
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Am Heart J 157:1035-41. 2009
    ....
  62. doi request reprint Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF
    Gregg C Fonarow
    Department of Medicine, UCLA University of California, Los Angeles Medical Center, Los Angeles, CA 90095 1679, USA
    Arch Intern Med 168:847-54. 2008
    ..This study evaluated the association between precipitating factors identified at the time of HF hospital admission and subsequent clinical outcomes...
  63. doi request reprint Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)
    William T Abraham
    Division of Cardiology, The Ohio State University, Columbus, Ohio, USA
    J Am Coll Cardiol 52:347-56. 2008
    ..The aim of this study was to develop a clinical model predictive of in-hospital mortality in a broad hospitalized heart failure (HF) patient population...
  64. ncbi request reprint Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
    Gregg C Fonarow
    Department of Medicine, University of California Los Angeles Medical Center, 10833 LeConte Ave, Room 47 123 CHS, Los Angeles, CA 90095 1679, USA
    Arch Intern Med 167:1493-502. 2007
    ..We sought to evaluate the effect of a national hospital-based initiative on quality of care in patients hospitalized with HF...
  65. doi request reprint Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan
    Paul J Hauptman
    Division of Cardiology, Department of Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA
    J Card Fail 19:390-7. 2013
    ..Relatively little has been documented regarding the clinical course of these patients during standard in-hospital management or with vasopressin antagonism...
  66. doi request reprint Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) t
    Andrew P Ambrosy
    Department of Medicine, Stanford University School of Medicine, CA, USA
    Am Heart J 165:216-25. 2013
    ..The prognostic value of SBP after initiating inhospital therapy and the mode of death and etiology of cardiovascular readmissions based on SBP have not been well characterized in HHF...
  67. ncbi request reprint Review of current and investigational pharmacologic agents for acute heart failure syndromes
    David D Shin
    Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA, and Division of Cardiology, European Hospital, Rome, Italy
    Am J Cardiol 99:4A-23A. 2007
    ..This article reviews a selection of current and investigational agents for the treatment of AHFS, with a main focus on the high-risk patient population with AHFS/LO...
  68. doi request reprint Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment
    Muthiah Vaduganathan
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Cardiovasc Med (Hagerstown) 13:415-22. 2012
    ..We sought to determine the short-term hemodynamic effects of tolvaptan in this high-risk population...
  69. doi request reprint A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF
    Gregg C Fonarow
    Department of Medicine, UCLA Medical Center, Los Angeles, CA, USA
    Eur Heart J 29:1983-91. 2008
    ..This study aimed to ascertain the relationship between smoking and clinical outcomes in patients hospitalized with heart failure (HF)...
  70. doi request reprint Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial
    James E Udelson
    Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 52:1540-5. 2008
    ..This study sought to assess the acute hemodynamic effect of vasopressin V(2) receptor antagonism...
  71. ncbi request reprint Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF
    Gregg C Fonarow
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California 90095 1679, USA
    J Card Fail 13:722-31. 2007
    ..The objective of this study was to prospectively evaluate beta-blocker use at hospital discharge as an indicator of quality of care and outcomes in patients with heart failure (HF)...
  72. doi request reprint Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)
    Liviu Klein
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circ Heart Fail 1:25-33. 2008
    ..Less is known about the changes and relationships among these variables and the postdischarge survival rate...
  73. doi request reprint Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)
    Gregg C Fonarow
    Department of Medicine, Ahmanson UCLA Cardiomyopathy Center, UCLA Medical Center, Los Angeles, CA 90095 1679, USA
    Circulation 122:585-96. 2010
    ....
  74. doi request reprint Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF
    Gregg C Fonarow
    Department of Medicine, Ahmanson UCLA Cardiomyopathy Center, UCLA Medical Center, Los Angeles, CA 90095 1679, USA
    Circ Heart Fail 1:98-106. 2008
    ..IMPROVE HF is a prospective cohort study designed to characterize current management of patients with chronic HF and ejection fraction < or =35% in a national registry of 167 US outpatient cardiology practices...
  75. doi request reprint Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failur
    Joseph S Rossi
    Northwestern University, Chicago, Illinois, United States
    Eur J Heart Fail 10:1215-23. 2008
    ..Coronary artery disease (CAD) is frequent among patients hospitalized with acute heart failure syndromes (AHFS)...
  76. doi request reprint Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program
    Gregg C Fonarow
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California 90095 1679, USA
    J Am Coll Cardiol 52:190-9. 2008
    ..This study ascertains the relationship between continuation or withdrawal of beta-blocker therapy and clinical outcomes in patients hospitalized with systolic heart failure (HF)...
  77. ncbi request reprint Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design
    Gregg C Fonarow
    Department of Medicine, UCLA Medical Center, Los Angeles, Calif, USA
    Am Heart J 148:43-51. 2004
    ..The ultimate aim of this program is to improve the standard of HF care in the hospital and outpatient settings and increase the use of evidence-based therapeutic strategies to save lives...
  78. doi request reprint Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial
    John E A Blair
    Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Am J Ther 15:231-40. 2008
    ....
  79. doi request reprint Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
    John E A Blair
    Division of Cardiology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Suite 600, Chicago, IL 60611, USA
    Eur Heart J 30:1666-73. 2009
    ..We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial...
  80. ncbi request reprint Managed care interventions for improving outcomes in acute heart failure syndromes
    Sadiya Sana Khan
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, 201 E Huron St, Galter 10 240, Chicago, IL 60611, USA
    Am J Manag Care 14:S273-86; quiz S287-91. 2008
    ....
  81. ncbi request reprint The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications
    Wendy A Gattis
    Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Rev Cardiovasc Med 3:S48-54. 2002
    ..The trial data will determine if in-hospital initiation of beta-blocker therapy is effective at improving the long-term use of pharmacologic agents proven to reduce morbidity and mortality...
  82. ncbi request reprint Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure
    Wendy A Gattis
    Duke University Medical Center Duke Clinical Research Institute, Division of Cardiology, Durham, North Carolina 27705, USA
    Am J Cardiol 91:169-74. 2003
    ..These results also suggest that caution should be taken when withdrawing beta blockade in this population...
  83. ncbi request reprint Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial
    Wendy A Gattis
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 43:1534-41. 2004
    ....
  84. doi request reprint Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients
    Matthew E Harinstein
    Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Am J Ther 15:206-13. 2008
    ..Given the unique metabolic needs of the failing heart, the role of micronutrients in combination with standard therapy warrants further investigation...
  85. ncbi request reprint Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization
    Parag Jain
    Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S3-17. 2003
  86. ncbi request reprint Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study
    Liviu Klein
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 93:44A-46A. 2004
    ....
  87. ncbi request reprint Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations
    Liviu Klein
    Advocate Illinois Masonic Medical Center, Chicago, Illinois 60607, USA
    Am J Cardiol 91:18F-40F. 2003
    ..Finally, anticoagulation is recommended only in patients who have concomitant atrial fibrillation or a previous history of cerebral or systemic emboli...
  88. ncbi request reprint Are the American College of Cardiology/Emergency Cardiac Care (ACC/ECC) guidelines useful in triaging patients to telemetry units?
    Jay Tiongson
    Northwestern University, Division of Cardiology, Chicago, IL 60611, USA
    Acute Card Care 8:155-60. 2006
    ....
  89. ncbi request reprint Evidence-based use of levosimendan in different clinical settings
    Leonardo De Luca
    Division of Cardiology, European Hospital, Rome, Italy
    Eur Heart J 27:1908-20. 2006
    ..This review summarizes the evidence from published scientific literature regarding the use of levosimendan in various clinical settings...
  90. doi request reprint Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
    Umberto Campia
    Center for Cardiovascular Quality and Outcomes, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 1006, Chicago, IL 60611, USA
    Curr Heart Fail Rep 7:100-9. 2010
    ..Further investigations are needed to confirm and expand the effectiveness and safety of these agents in patients with acute heart failure and low cardiac output...
  91. ncbi request reprint Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure
    Hani N Sabbah
    Division of Cardiovascular Medicine, Department of Medicine, Henry Ford Health System, Detroit, Michigan 48202, USA
    Am J Cardiol 99:41A-46A. 2007
    ..These results suggest that istaroxime may be a unique positive luso-inotropic agent for the treatment of patients with ADHF...
  92. ncbi request reprint Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy
    David Bello
    Feinberg Cardiovascular Research Institute, Division of Cardiology, Northwestern University, Chicago, Ill, USA
    Circulation 108:1945-53. 2003
    ..We hypothesized that gadolinium-enhanced cardiovascular magnetic resonance imaging (CMR) can predict reversible myocardial dysfunction and remodeling in heart failure patients treated with beta-blockers...
  93. pmc New York Heart Association functional class predicts exercise parameters in the current era
    Stuart D Russell
    Department of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Am Heart J 158:S24-30. 2009
    ..Using baseline data from the HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) study, we examined this relationship...
  94. ncbi request reprint B-type natriuretic peptide: from bench to bedside
    Kirkwood F Adams
    Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7075, USA
    Am Heart J 145:S34-46. 2003
  95. ncbi request reprint Role of neurohormonal modulators in heart failure with relatively preserved systolic function
    Jonathan A Rapp
    Northwestern University, Chicago, IL 60611, USA
    Heart Fail Clin 1:77-93. 2005
  96. pmc Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods
    Ali Ahmed
    Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, and Center for Heart Failure Research, University of Alabama at Birmingham and VA Medical Center, 35294 2041, USA
    Eur Heart J 27:1431-9. 2006
    ..Yet, the long-term effects of chronic diuretic use in HF are largely unknown. We retrospectively analysed the Digitalis Investigation Group (DIG) data to determine the effects of diuretics on HF outcomes...
  97. ncbi request reprint Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period
    Francesco Borrello
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Rev Cardiovasc Med 4:S13-24. 2003
    ..Given the considerable evidence from randomized clinical trials, the use of beta-blockers is recommended in all post-MI patients without a contraindication, particularly in those with left ventricular systolic dysfunction...
  98. ncbi request reprint Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department
    Sean Collins
    University of Cincinnati, Department of Emergency Medicine, Cincinnati, OH 45267, USA
    Ann Emerg Med 51:45-57. 2008
    ..This article proposes such a paradigm shift in acute heart failure syndrome care and discusses areas of further research that are necessary to promote this change in approach...
  99. ncbi request reprint Carvedilol: beta-blockade and beyond
    Alice F Stroe
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Rev Cardiovasc Med 5:S18-27. 2004
    ....
  100. ncbi request reprint Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction
    Emil Thattassery
    Division of Cardiology, Northwestern University Feinberg School of Medicine, 33 West Ontario, 25G Chicago, IL 60610, USA
    Heart Fail Rev 9:107-13. 2004
    ....
  101. ncbi request reprint Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial
    Joseph Rossi
    Feinberg School of Medicine Northwestern University, Chicago, Illinois 60611, USA
    Acute Card Care 9:82-6. 2007
    ..Hyponatremia predicts poor outcome in patients with acute heart failure syndromes. This study evaluated the relationship between baseline serum sodium, change in serum sodium, and 60-day mortality in hospitalized heart failure patients...